Literature DB >> 1717155

Neovascularization is associated with a switch to the export of bFGF in the multistep development of fibrosarcoma.

J Kandel1, E Bossy-Wetzel, F Radvanyi, M Klagsbrun, J Folkman, D Hanahan.   

Abstract

In a transgenic mouse model, dermal fibrosarcomas develop in a pathway comprised of at least three stages: mild fibromatosis, aggressive fibromatosis, and fibrosarcoma. The latter two stages are highly vascularized when compared with both the normal dermis and the initial mild lesion. Analysis of cell cultures derived from biopsies of these lesions has revealed that basic fibroblast growth factor (bFGF) is synthesized in all three stages and in normal dermal fibroblasts derived from the same mice. Unexpectedly, there is a change in the localization of bFGF from its normal cell-associated state to extracellular release in the latter two stages, which is concomitant both with the neovascularization seen in vivo and with the tumorigenicity of these cell lines. Thus, in this multistep tumorigenesis pathway there appears to be a discrete switch to the angiogenic phenotype that correlates with the export of bFGF, a known angiogenic factor.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1717155     DOI: 10.1016/0092-8674(91)90033-u

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  99 in total

1.  N-arginine dibasic convertase (nardilysin) isoforms are soluble dibasic-specific metalloendopeptidases that localize in the cytoplasm and at the cell surface.

Authors:  V Hospital; V Chesneau; A Balogh; C Joulie; N G Seidah; P Cohen; A Prat
Journal:  Biochem J       Date:  2000-07-15       Impact factor: 3.857

2.  The role of the vascular phase in solid tumor growth: a historical review.

Authors:  D Ribatti; A Vacca; F Dammacco
Journal:  Neoplasia       Date:  1999-10       Impact factor: 5.715

3.  A novel way to get out of the cell.

Authors:  A Rubartelli; A Bajetto; N Bonifaci; E Di Blas; E Solito; R Sitia
Journal:  Cytotechnology       Date:  1993-01       Impact factor: 2.058

4.  Ultrastructural immunolocalization of basic fibroblast growth factor in endothelial cells: morphologic evidence for unconventional secretion of a novel protein.

Authors:  Ranan Gulhan Aktas; Robert J Kayton
Journal:  J Mol Histol       Date:  2011-08-10       Impact factor: 2.611

5.  Inhibition of tumor angiogenesis using a soluble receptor establishes a role for Tie2 in pathologic vascular growth.

Authors:  P Lin; P Polverini; M Dewhirst; S Shan; P S Rao; K Peters
Journal:  J Clin Invest       Date:  1997-10-15       Impact factor: 14.808

6.  Effect of fibroblast growth factor saporin mitotoxins on human bladder cell lines.

Authors:  T A Tetzke; M C Caton; P A Maher; Z Parandoosh
Journal:  Clin Exp Metastasis       Date:  1997-11       Impact factor: 5.150

7.  Induction of vascular endothelial tubular morphogenesis by human glioma cells. A model system for tumor angiogenesis.

Authors:  T Abe; K Okamura; M Ono; K Kohno; T Mori; S Hori; M Kuwano
Journal:  J Clin Invest       Date:  1993-07       Impact factor: 14.808

8.  Exon switching and activation of stromal and embryonic fibroblast growth factor (FGF)-FGF receptor genes in prostate epithelial cells accompany stromal independence and malignancy.

Authors:  G Yan; Y Fukabori; G McBride; S Nikolaropolous; W L McKeehan
Journal:  Mol Cell Biol       Date:  1993-08       Impact factor: 4.272

9.  Interferon-alpha and interleukin 2 synergistically enhance basic fibroblast growth factor synthesis and induce release, promoting endothelial cell growth.

Authors:  F Cozzolino; M Torcia; M Lucibello; L Morbidelli; M Ziche; J Platt; S Fabiani; J Brett; D Stern
Journal:  J Clin Invest       Date:  1993-06       Impact factor: 14.808

10.  Reactivation of proliferin gene expression is associated with increased angiogenesis in a cell culture model of fibrosarcoma tumor progression.

Authors:  D J Toft; S B Rosenberg; G Bergers; O Volpert; D I Linzer
Journal:  Proc Natl Acad Sci U S A       Date:  2001-10-23       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.